Clinical trial / 2000
Oral NADH supplementation for 3 months showed no evidence of cognitive improvement in patients with mild to moderate dementia.
Researchers conducted a 3-month open-label study administering 10 mg/day of oral reduced nicotinamide adenine dinucleotide (NADH) to 25 patients with mild to moderate dementia alongside their current cholinomimetic medication. Among the 19 patients who completed the study, no evidence was found for any cognitive effect assessed by established psychometric tests. The authors concluded that NADH is unlikely to produce cognitive improvements of the magnitude reported earlier.
- Study type
- 3-month open-label study
- Who was studied
- 25 patients with mild to moderate dementia (Alzheimer, vascular, fronto-temporal)
- What was measured
- Cognitive effect as defined by established psychometric tests
THE PAPER
No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia.
Rainer M, Kraxberger E, Haushofer M, Mucke HA, Jellinger KA. J Neural Transm (Vienna), 2000.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.